Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Recombinant DNA01:09

Recombinant DNA

Overview
Recombinant DNA01:09

Recombinant DNA

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variability in the application of patient blood management programs in the Iberian peninsula.

Revista espanola de anestesiologia y reanimacion·2026
Same author

[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].

Medicina intensiva·2024
Same author

Utility of the central venous-to-arterial CO<sub>2</sub> difference to predict adverse outcomes after liver transplantation.

Revista espanola de anestesiologia y reanimacion·2022
Same author

Effects of vaccination against COVID-19 on the evolution of critically ill patients.

Medicina intensiva·2022
Same author

PBM: Now more than ever necessary.

Revista espanola de anestesiologia y reanimacion·2022
Same author

Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19.

Medicina intensiva·2022

Related Experiment Video

Updated: Jul 13, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

[Recombinant activated Factor VII].

M Quintana Díaz1, M Sánchez Casado, A García de Lorenzo y Mateos

  • 1Unidad de Cuidados Intensivos, Hospital Nuestra Señora del Prado, Talavera de la Reina, Toledo, Spain. mquintanadiaz@arrakis.es

Medicina Intensiva
|August 1, 2007
PubMed
Summary

Recombinant activated factor VII (rFVIIa) is crucial for managing massive bleeding by activating the coagulation cascade. Its use is expanding beyond hemophilia to intracranial bleeding and trauma, requiring careful risk assessment.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Related Experiment Videos

Last Updated: Jul 13, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Context:

  • Recombinant activated factor VII (rFVIIa) is a procoagulant medication.
  • Its mechanism involves binding to tissue factor to initiate the coagulation cascade.
  • rFVIIa is approved for bleeding episodes in hemophilia patients.

Purpose:

  • To explore the expanding indications for recombinant activated factor VII.
  • To highlight its use in critical bleeding scenarios beyond hemophilia.
  • To emphasize the need for risk-benefit analysis in patient care.

Summary:

  • Recombinant activated factor VII (rFVIIa) is indicated for massive bleeding, including non-traumatic intracranial hemorrhage and severe trauma.
  • It triggers the coagulation cascade upon binding to tissue factor.
  • While effective, its relatively recent widespread use necessitates careful consideration of potential risks.

Impact:

  • Facilitates management of life-threatening bleeding conditions.
  • Broadens therapeutic options for coagulopathies.
  • Informs clinical decision-making regarding the safe and effective use of rFVIIa.